Related references
Note: Only part of the references are listed.Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: an observational study based on the global burden of diseases
Kaimin Hu et al.
BMJ OPEN (2019)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study
Arlindo R. Ferreira et al.
BREAST (2018)
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
Adam M. Brufsky et al.
ONCOLOGIST (2018)
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2018)
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
Li Li et al.
BMC CANCER (2018)
The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells
Denis G. Alferez et al.
CURRENT STEM CELL REPORTS (2018)
Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs
Todd P. Knutson et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Hanxiao Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis
Valentina Cocciolone et al.
ONCOTARGET (2017)
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis
Hadar Goldvaser et al.
CANCER TREATMENT REVIEWS (2017)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
Huan Jin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Raimund Jakesz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
Lisa K. Dunnwald et al.
BREAST CANCER RESEARCH (2007)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Prognostic factors in node-negative breast cancer - A review of studies with sample size more than 200 and follow-up more than 5 years
AN Mirza et al.
ANNALS OF SURGERY (2002)
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years
HJ Stewart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
